[Can complement blocking arrest peritoneal fibrosis?].
Esposito
Vittoria
V
Div. of Experimental Diabetes and Aging, Mount Sinai Medical School, New York, USA. vittoriaesposito@libero.it
D000818:Animals; D003167:Complement Activation / Q000187:drug effects*; D051056:Complement Inactivating Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003165:Complement System Proteins / Q000187:drug effects*; D004359:Drug Therapy, Combination; D004546:Elapid Venoms / Q000494:pharmacology / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D056627:Peritoneal Fibrosis / Q000473:pathology / Q000517:prevention & control*; D011951:Receptors, Complement / Q000627:therapeutic use; D016896:Treatment Outcome
D051056:Complement Inactivating Agents; D004546:Elapid Venoms; D011951:Receptors, Complement; C016310:cobra venom factor; C082885:soluble complement inhibitor 1; D003165:Complement System Proteins